130 related articles for article (PubMed ID: 23241050)
21. Dialysis and transplantation in Fabry disease: indications for enzyme replacement therapy.
Mignani R; Feriozzi S; Schaefer RM; Breunig F; Oliveira JP; Ruggenenti P; Sunder-Plassmann G
Clin J Am Soc Nephrol; 2010 Feb; 5(2):379-85. PubMed ID: 20056752
[TBL] [Abstract][Full Text] [Related]
22. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.
Sims K; Politei J; Banikazemi M; Lee P
Stroke; 2009 Mar; 40(3):788-94. PubMed ID: 19150871
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular events in patients with fabry disease natural history data from the fabry registry.
Patel MR; Cecchi F; Cizmarik M; Kantola I; Linhart A; Nicholls K; Strotmann J; Tallaj J; Tran TC; West ML; Beitner-Johnson D; Abiose A
J Am Coll Cardiol; 2011 Mar; 57(9):1093-9. PubMed ID: 21349401
[TBL] [Abstract][Full Text] [Related]
24. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of Fabry Disease in Young Patients with Stroke in Argentina.
Reisin RC; Mazziotti J; Cejas LL; Zinnerman A; Bonardo P; Pardal MF; Martínez A; Riccio P; Ameriso S; Bendersky E; Nofal P; Cairola P; Jure L; Sotelo A; Rozenfeld P; Ceci R; Casas-Parera I; Sánchez-Luceros A;
J Stroke Cerebrovasc Dis; 2018 Mar; 27(3):575-582. PubMed ID: 29132836
[TBL] [Abstract][Full Text] [Related]
26. [Fabry disease: demographic data since introduction of enzyme replacement therapy].
Cybulla M; Walter K; Neumann HP; Widmer U; Schärer M; Sunder-Plassmann G; Jansen T; Rolfs A; Beck M
Dtsch Med Wochenschr; 2007 Jul; 132(28-29):1505-9. PubMed ID: 17607649
[TBL] [Abstract][Full Text] [Related]
27. Fabry disease: treatment and diagnosis.
Rozenfeld PA
IUBMB Life; 2009 Nov; 61(11):1043-50. PubMed ID: 19859978
[TBL] [Abstract][Full Text] [Related]
28. [Fabry disease in Italy: first epidemiologic and collaborative study].
Ricci R; Castorina M; Di Lillo M; Antuzzi D; Frustaci A; Parini R; Menni F; Furlan F; Burlina A; Burlina A; Catuogno S; Gabrielli O; Burattini I; Borsini W; Buchner S; Ferriozzi S; Spisni C; De Vito R; Di Rocco M; Aricò M; Pistone G; Bongiorno AM; Morrone A; Cavicchi C; Zammarchi E
Ann Ital Med Int; 2004; 19(4):269-75. PubMed ID: 15678707
[TBL] [Abstract][Full Text] [Related]
29. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey.
Lidove O; Ramaswami U; Jaussaud R; Barbey F; Maisonobe T; Caillaud C; Beck M; Sunder-Plassmann G; Linhart A; Mehta A;
Int J Clin Pract; 2006 Sep; 60(9):1053-9. PubMed ID: 16939546
[TBL] [Abstract][Full Text] [Related]
30. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.
Arends M; Wijburg FA; Wanner C; Vaz FM; van Kuilenburg ABP; Hughes DA; Biegstraaten M; Mehta A; Hollak CEM; Langeveld M
Mol Genet Metab; 2017 Jun; 121(2):157-161. PubMed ID: 28495078
[TBL] [Abstract][Full Text] [Related]
31. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry.
Beck M; Ramaswami U; Hernberg-Ståhl E; Hughes DA; Kampmann C; Mehta AB; Nicholls K; Niu DM; Pintos-Morell G; Reisin R; West ML; Schenk J; Anagnostopoulou C; Botha J; Giugliani R
Orphanet J Rare Dis; 2022 Jun; 17(1):238. PubMed ID: 35725623
[TBL] [Abstract][Full Text] [Related]
32. Hearing loss in Fabry disease: data from the Fabry Outcome Survey.
Hegemann S; Hajioff D; Conti G; Beck M; Sunder-Plassmann G; Widmer U; Mehta A; Keilmann A
Eur J Clin Invest; 2006 Sep; 36(9):654-62. PubMed ID: 16919049
[TBL] [Abstract][Full Text] [Related]
33. A successful approach for the detection of Fabry patients in Argentina.
Rozenfeld PA; Tarabuso A; Ebner R; Ramallo G; Fossati CA
Clin Genet; 2006 Apr; 69(4):344-8. PubMed ID: 16630168
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of uncontrolled hypertension in patients with Fabry disease.
Kleinert J; Dehout F; Schwarting A; de Lorenzo AG; Ricci R; Kampmann C; Beck M; Ramaswami U; Linhart A; Gal A; Houge G; Widmer U; Mehta A; Sunder-Plassmann G
Am J Hypertens; 2006 Aug; 19(8):782-7. PubMed ID: 16876675
[TBL] [Abstract][Full Text] [Related]
35. The hearing status in 12 female and 15 male Japanese Fabry patients.
Sakurai Y; Kojima H; Shiwa M; Ohashi T; Eto Y; Moriyama H
Auris Nasus Larynx; 2009 Dec; 36(6):627-32. PubMed ID: 19261412
[TBL] [Abstract][Full Text] [Related]
36. The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy.
Schmied C; Nowak A; Gruner C; Olinger E; Debaix H; Brauchlin A; Frank M; Reidt S; Monney P; Barbey F; Shah D; Namdar M
Heart; 2016 Aug; 102(16):1309-14. PubMed ID: 27056970
[TBL] [Abstract][Full Text] [Related]
37. Fabry disease in latin america: data from the fabry registry.
Villalobos J; Politei JM; Martins AM; Cabrera G; Amartino H; Lemay R; Ospina S; Ordoñez SS; Varas C
JIMD Rep; 2013; 8():91-9. PubMed ID: 23430525
[TBL] [Abstract][Full Text] [Related]
38. Impact of measures to enhance the value of observational surveys in rare diseases: the Fabry Outcome Survey (FOS).
Clarke JT; Giugliani R; Sunder-Plassmann G; Elliott PM; Pintos-Morell G; Hernberg-Ståhl E; Malmenäs M; Beck M;
Value Health; 2011; 14(6):862-6. PubMed ID: 21914507
[TBL] [Abstract][Full Text] [Related]
39. Major cardiovascular adverse events in Fabry disease patients receiving agalsidase alfa.
Ferrari G; Reisin R; Kisinovsky I; Neumann P; Dragonetti L; Cáceres G; Choua M; Rozenfeld P; Marchesoni C; Finn V;
Medicina (B Aires); 2021; 81(2):173-179. PubMed ID: 33906135
[TBL] [Abstract][Full Text] [Related]
40. Age-related renal function decline in Fabry disease patients on enzyme replacement therapy: a longitudinal cohort study.
Madsen CV; Granqvist H; Petersen JH; Rasmussen ÅK; Lund AM; Oturai P; Sørensen SS; Feldt-Rasmussen U
Nephrol Dial Transplant; 2019 Sep; 34(9):1525-1533. PubMed ID: 30535327
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
